Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on November 7, 2005
Japanese Journal of Clinical Oncology 2005 35(11):680-689; doi:10.1093/jjco/hyi180
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
35/11/680    most recent
hyi180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pu, Y.-S.
Right arrow Articles by Myers, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pu, Y.-S.
Right arrow Articles by Myers, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Meeting Report

The 18th International Symposium: Controversies in Prostate Cancer Diagnosis and Treatment

Yeong-Shiau Pu1, Hiroyuki Fujimoto2, Tadao Kakizoe3 and Robert Myers4

1 Department of Urology, National Taiwan University Hospital, Taipei, Taiwan, 2 Urology Division, National Cancer Center Hospital, 3 National Cancer Center, Tokyo, Japan and 4 Department of Urology, Mayo Clinic College of Medicine, MN, USA

For reprints and all correspondence: Yeong-Shiau Pu, Department of Urology, National Taiwan University Hospital, Taipei, Taiwan. E-mail: yspu@ha.mc.ntu.edu.tw; ys.pu@msa.hinet.net

Received August 16, 2005; accepted September 7, 2005

Abbreviations: ADT, androgen-deprivation therapy • AR, androgen receptor • BPH, benign prostatic hyperplasia • BCR, biochemical recurrence • DRE, digital rectal examination • 3D-CRT, 3-dimension conformal radiotherapy • EORTC, European Organization for Research and Treatment of Cancer • ED, erectile dysfunction • EBRT, external beam radiotherapy • GS, Gleason's score • HRPC, hormone-refractory prostate cancer • IMRT, intensity modulated radiotherapy • LHRHa, luteinizing hormone-releasing hormone agonist • MSKCC, Memorial Sloan-Kettering Cancer Center • NVB, neurovascular bundle • PZ, peripheral zone • PC, prostate cancer • PSA, prostate-specific antigen • PSADT, PSA-doubling time • PSAV, PSA velocity • QOL, quality-of-life • RP, radical prostatectomy • RT, radiotherapy • TZ, transition zone • TRUS, transrectal ultrasonography

The first 150 words of the full text of this article appear below.


   INTRODUCTION
 
The 18th International Symposium of the Foundation for the Promotion of Cancer Research, ‘Controversies in Prostate Cancer: Diagnosis and Treatment’ was held in Tokyo on 24–26 January 2005. The symposium was organized by Drs Tadao Kakizoe, Robert Myers, Hiroyuki Fujimoto and Yoichi Arai with Dr Takashi Sugimura as the advisor.


   WELCOME AND INTRODUCTION
 
Dr Kakizoe chaired the session and expressed his sincere concerns about the ongoing big snow storm in the United States. Professor T. Sugimura opened the Eighteenth International Symposium. Since 1988, 578 speakers from 24 nations around the world have been invited to discuss various cancers comprehensively, usually one cancer at a time. This was the second time where prostate cancer (PC) was discussed. Dr Sugimura pointed out that prostate-specific antigen (PSA) has made a huge progress possible since late 1970s. Dr Sugimura then used himself as an example to explain the notion of cancer survivor. The Japanese Emperor is also . . . [Full Text of this Article]


   OPENING REMARKS: PROSTATE CANCER—A CHALLENGE FOR THE 21ST CENTURY
 

   SESSION 1: EPIDEMIOLOGY AND PATHOLOGY
 
CHAIRPERSON: DAVID BOSTWICK
PROSTATE CANCER: CONTROLLING THE EPIDEMIC (BY PETER BOYLE)
ACTIVE MONITORING USING PSA-DOUBLING TIME FOR STAGE T1C PROSTATE CANCER WITH FAVORABLE BIOPSY FEATURES (BY YOSHIYUKI KAKEHI)
CHAIRPERSON: YEONG-SHIAU PU
LATENT PROSTATE CANCER: CURRENT CONCEPTS (BY DAVID BOSTWICK)
LATENT CANCER, NODULAR HYPERPLASIA AND DIFFUSE ENLARGEMENT OF THE PROSTATE: MORPHOMETRIC AND HISTOPATHOLOGICAL ANALYSES (BY TAIZO SHIRAISHI)
FAMILIAL PROSTATE CANCER (BY KAZUHIRO SUZUKI)

   SESSION 2: PREVENTION AND DIAGNOSIS
 
CHAIRPERSON: PETER BOYLE
PRO'S AND CON'S OF SCREENING FOR PROSTATE CANCER IN 2005 (BY FRITZ SCHRöDER)
CURRENT CONTROVERSIES IN PROSTATE CANCER SCREENING (BY WILLIAM CATALONA)
SCREENING, BIOPSY AND LIFE EXPECTANCY (BY HIDETOSHI YAMANAKA)
CHAIRPERSON: WILLIAM CATALONA
CANCER-ASSOCIATED CARBOHYDRATE ALTERATION OF PSA (BY CHIKARA OHYAMA)
MOLECULAR MARKERS OF PROSTATE CANCER (BY OSAMU OGAWA)
IMAGING MODALITIES FOR STAGING PROSTATE CANCER (BY HISATAKA KOBAYASHI)
CHAIRPERSON: WILLIAM CATALONA
CHEMOPREVENTION OF PROSTATE CANCER: ASSESSING BENEFIT AND RISK IN THE PROSTATE CANCER PREVENTION TRIAL (CONTENTS BY ERIC KLEIN; PRESENTED BY WILLIAM CATALONA)
EQUOL: ONE ISOFLAVONE FOR CHEMOPREVENTION OF PROSTATE CANCER (BY HIDEYUKI AKAZA)

   SESSION 3: THERAPY OF LOCALIZED PROSTATE CANCER
 
CHAIRPERSON: PETER SCARDINO
HYPOFRACTIONATED CARBON-ION RADIOTHERAPY FOR PROSTATE CANCER (BY HIROHIKO TSUJII)
RADICAL RETROPUBIC PROSTATECTOMY (BY ROBERT MYERS)
FUNCTIONAL OUTCOME OF RADICAL PROSTATECTOMY (BY YOICHI ARAI)

   SESSION 4: CURRENT FAR EAST STATUS OF PROSTATE CANCER
 
CHAIRPERSON: FRITZ SCHRöDER
STATUS OF PROSTATE CANCER IN KOREA (BY CHONGWOOK LEE)
STATUS OF PROSTATE CANCER IN TAIWAN (BY YEONG-SHIAU PU)

   SESSION 5: MOLECULAR BIOLOGY AND NOVEL THERAPIES
 
CHAIRPERSON: EDWARD MESSING
FUNCTION OF ANDROGEN RECEPTOR IN PROSTATE CANCER DEVELOPMENT (BY SHIGEAKI KATO)
PERSONALIZED PEPTIDE VACCINATION FOR PROSTATE CANCER (BY KYOGO ITOH)
IN SITU GENE THERAPY FOR PROSTATE CANCER (BY HIROMI KUMON)

   SESSION 6: THERAPY OF N+ AND ADVANCED PROSTATE CANCER
 
CHAIRPERSON: CHONGWOOK LEE
HORMONAL THERAPY FOR PROSTATE CANCER: TIMING AND CONTROVERSIES (BY EDWARD MESSING)
CHEMOTHERAPY FOR ADVANCED PROSTATE CANCER (BY DAVID SOLIT)

   SESSION 7: THERAPY OF LOCALLY ADVANCED PROSTATE CANCER
 
CHAIRPERSON: DAVID SOLIT
RISING PSA AFTER RADICAL PROSTATECTOMY: RESULTS OF RADIATION AND OF ANDROGEN DEPRIVATION THERAPY (BY PETER SCARDINO)
TREATMENT OF PATIENTS WITH PSA RECURRENCE AFTER RADICAL PROSTATECTOMY (BY SEIJI NAITO)
CHAIRPERSON: HISATAKA KOBAYASHI
EXTERNAL BEAM RADIOTHERAPY FOR PROSTATE CANCER (BY MINAKO SUMI)
THE ROLE OF HIGH-DOSE EXTERNAL BEAM RADIOTHERAPY IN THE TREATMENT OF PROSTATE CANCER (BY MICHAEL ZELEFSKY)
WIDE RESECTION OF THE PROSTATE WITH NEOADJUVANT HORMONE THERAPY (BY HIROYUKI FUJIMOTO)
CHAIRPERSON: ROBERT MYERS
IMPROVED OUTCOMES WITH CONFORMAL PROSTATE BRACHYTHERAPY IN THE TREATMENT OF CLINICALLY LOCALIZED PROSTATE CANCER (BY MICHAEL ZELEFSKY)
THE ROLE OF SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY (BY MICHAEL ZELEFSKY)
WHY IS PROSTATE CANCER INCREASING IN ASIAN COUNTRIES INCLUDING JAPAN? (BY TAIJI TSUKAMOTO)

   CLOSING
 
CHAIRPERSON: ROBERT MYERS
SUMMARY OF SYMPOSIUM AND CLOSING REMARKS (BY TADAO KAKIZOE)

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?